Overview

ATX-MS-1467 in Multiple Sclerosis

Status:
Completed

Trial end date:
2016-04-30

Target enrollment:

Participant gender:

Summary

This is a multi-center, open-label, single arm, baseline-controlled Phase 2a trial to evaluate the clinical and biological effects of ATX-MS-1467 in subjects with relapsing multiple sclerosis (MS) and to assess the maintenance of any such effects.

Phase:

Phase 2

Details

Lead Sponsor:

Merck KGaA
Merck KGaA, Darmstadt, Germany